Skip to content

ScreenTalk to Improve Colorectal Cancer Screening Uptake Among First-degree Relatives of Patients: a Study Protocol

An Intelligent Voice-interactive Tailored Communication System (ScreenTalk) for Enhancing Colorectal Cancer Screening Among First-degree Relatives of Patients: a Randomized Type I Hybrid Effectiveness-implementation Trial

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06710860
Enrollment
314
Registered
2024-11-29
Start date
2025-07-31
Completion date
2026-07-31
Last updated
2025-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colonoscopy, Colorectal Cancer, First-degree Relatives

Keywords

Colonoscopy, First-degree relatives, Cancer screening, Artificial intelligence, Speech technology, Type I hybrid effectiveness-implementation trial, RE-AIM framework

Brief summary

Participants in intervention group will receive the ScreenTalk intervention consisting of 3 module: measurement module, algorithmic tailoring module, and open dialogue module. The primary outcome, CRC screening uptake will be verified by medical records; and health belief will be measured at baseline, 3, 6, 9 and 12 months.

Detailed description

This study will follow a hybrid type I effectiveness-implementation trial design. A cluster-randomized controlled trial will be conducted to examine the effectiveness of the intelligent voice-interactive tailored communication system. ScreenTalk can automatically tailor screening recommendations based on risk and psychosocial characteristic assessments by leveraging intelligent speech interaction (ISI) technology. The three components of the ScreenTalk intervention are as follows: (1) a measurement module, (2) an algorithmic tailoring module, and (3) an open dialogue module. All participants will be required to complete 3 modules within 1 month. If the intervention group does not undergo CRC screening at the follow-up time point, the system will repeatedly provide tailored communication intervention to further enhance the CRC risk perception of FDRs based on the current evaluation results. The implementation outcomes will be guided by the RE-AIM framework. Both qualitative and quantitative methods will be employed to evaluate implementation outcomes and determine the factors that may influence implementation process. CRC screening uptake verified by medical records and health belief will be measured at baseline, 3, 6, 9 and 12 months.

Interventions

BEHAVIORALThe intelligent voice-interactive tailored communication system-based intervention

Participants in intervention group will receive the ScreenTalk intervention consisting of 3 modules:(1) a measurement module, (2) an algorithmic tailoring module, and (3) an open di-alogue module. All participants will be required to complete 3 modules within 1 month. If the intervention group does not undergo CRC screening at the follow-up time point, the system will repeatedly provide tailored communication intervention to further enhance the CRC risk perception of FDRs based on the current evaluation results. The primary outcome (uptake of CRC screening) will be measured at 3 months post-intervention (T1), 6 months post-intervention (T2), 9 months post-intervention (T3) and 12 months post-intervention (T4).

Sponsors

National Natural Science Foundation of China
CollaboratorOTHER_GOV
Sun Yat-sen University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Age 40 to 75 years or 10 years before the age at which the relative was diagnosed; * individuals with one FDR with CRC age \<60 years or with two or more FDRs with CRC at any age; * have not had a colonoscopy within 5 years; * access to WeChat themselves or through close family members living in the same household; * able to read and speak Chinese.

Exclusion criteria

* Have history of cancer or inflammatory bowel disease; * have history of a hereditary syndromes (Lynch syndrome or familial adenomatous polyposis); * recently participate in another study or previously participated in cancer risk counseling or study; * with doctor-diagnosed psychiatric illness.

Design outcomes

Primary

MeasureTime frameDescription
Participate rate of CRC screening3 months post-intervention (T1); 6 months post-intervention (T2); 9 months post-intervention (T3); 12 months post-intervention (T4)Uptake of colonoscopy or FOBT. Medical records will be collected from those who had undergone colonoscopy or fecal test. Only the examination records that are verified by medical records will be counted and involved in the data analysis.

Secondary

MeasureTime frameDescription
Perceived threatBaseline (T0); 3 months post-intervention (T1); 6 months post-intervention (T2); 9 months post-intervention (T3); 12 months post-intervention (T4)The Colorectal Cancer and Colonoscopy Screening Health Beliefs Scale for First-Degree Relatives (CCHBS-FDR), with 6 dimensions, will be used to measures perceived threat of CRC and colonoscopy screening, namely per-ceived susceptibility of CRC and perceived severity of CRC. Each item of CCHBS-FDR is rated on a five-point (1-5) Likert scale ranging from 1 (Strongly Disagree) to 5 (Strongly Agree), with scores ranging from 36 to 180. Higher scores on each dimension indicate higher levels of perception.
Perceived efficacyBaseline (T0); 3 months post-intervention (T1); 6 months post-intervention (T2); 9 months post-intervention (T3); 12 months post-intervention (T4)Perceived efficacy includes perceived benefits and self-efficacy. The Colorectal Cancer and Colonoscopy Screening Health Beliefs Scale for First-Degree Relatives (CCHBS-FDR) will be used to measures perceived efficacy of colonoscopy screening, and the four-item simplified Chinese version of the self-efficacy questionnaire will be used to assess the self-efficacy for participating in CRC screening. Each item of these two questionnaires is rated on a five-point (1-5) Likert scale ranging from 1 (Strongly Disagree) to 5 (Strongly Agree), with scores ranging from 36 to 180. Higher scores on each dimension indicate higher levels of perception.
Perceived barriersBaseline (T0); 3 months post-intervention (T1); 6 months post-intervention (T2); 9 months post-intervention (T3); 12 months post-intervention (T4)The Colorectal Cancer and Colonoscopy Screening Health Beliefs Scale for First-Degree Relatives (CCHBS-FDR) will be used to measures perceived barriers for participating in CRC screening. Each item of CCHBS-FDR is rated on a five-point (1-5) Likert scale ranging from 1 (Strongly Disagree) to 5 (Strongly Agree), with scores ranging from 36 to 180. Higher scores on each dimension indicate higher levels of perception.
Cue to actionBaseline (T0); 3 months post-intervention (T1); 6 months post-intervention (T2); 9 months post-intervention (T3); 12 months post-intervention (T4)Including three types of action cues: family history of CRC, physician's recommendation and health insurance coverage. The cue to action for CRC screening questionnaire will be used to collect information of cue to action among FDRs. Each item is rated on a five-point (1-5) Likert scale ranging from 1 (Strongly Disagree) to 5 (Strongly Agree). The score for cues to action was calculated by averaging the corresponding items (ranging from 1 to 5), with higher score indi-cating higher cue to action.

Other

MeasureTime frameDescription
Fidelity1 month post-intervention; post-implementationFidelity includes participants' adherence of each module and reasons for non-completion. Relevant data will be collected through the tailored communication system record.
Participant characteristicsBaseline (T0)A self-designed general information questionnaire will be used to collect participant characteristics.
Maintenance3 months post-intervention (T1); 6 months post-intervention (T2); 9 months post-intervention (T3); 12 months post-intervention (T4)Sustained engagement of participants at 3-month, 6-month, 9-month, and 12-month follow-up. Follow-up information of participants will be obtained through the implementation logbook and tailored communication system record.
Acceptability1-month post interventionThe User Feedback Questionnaire for ScreenTalk will be used to measure the satisfaction among the participant for ScreenTalk.
Percentage of contacted FDRs who participate in this studyBaseline (T0); 1 month post-interventionCollect data through information recorded in the Implementation logbook
Enrollment routesBaseline (T0)Including the recruitment approach and reasons for refusal to participate. It will be collected through the implementation logbook.
Representativeness of staff that participateBaseline (T0)The self-designed general information questionnaire for staff will be used to collect related data.
Barriers and facilitators to adoption13 months post-interventionQualitative interviews will be conducted to gain staff insights into intervention adoption.

Countries

China

Contacts

Primary ContactYang Bai
baiy36@mail.sysu.edu.cn+86 13922317606
Backup ContactShuya Lin
linshy75@mail2.sysu.edu.cn+86 13715154981

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026